Study wrapper · #514
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
Editor's note
This is a 6-month phase 2 randomized open-label trial (73 participants) testing whether tesamorelin improves neurocognitive impairment in virally suppressed people with HIV and abdominal obesity. Researchers reported that the tesamorelin group showed only a non-significant trend toward improved neurocognitive performance, with no significant between-group difference versus standard of care; IGF-1 rose but did not correlate with cognitive change. Tesamorelin was, however, associated with a greater reduction in waist circumference. The authors candidly flag key limitations: the study was underpowered and lacked a placebo arm (open-label design). The honest read is a null cognitive result — short-term abdominal-fat reduction did not translate into clear cognitive benefit — even though the peripheral metabolic effect (waist reduction) was consistent with tesamorelin's established profile.
Plain-language abstract
Researchers tested whether tesamorelin could help thinking and memory in 73 people with well-controlled HIV who also had abdominal obesity. Participants were randomly assigned to tesamorelin or usual care for six months. The tesamorelin group edged toward better scores on thinking tests, but the improvement was not statistically solid, and there was no clear difference between the two groups. Blood levels of IGF-1 (a growth-related hormone) rose with tesamorelin, but that rise did not track with any change in thinking or waistline. Tesamorelin was associated with a larger drop in waist size than usual care. The authors are upfront that the study was too small to detect subtle effects and had no placebo group, so it cannot show a cognitive benefit. Overall, shrinking abdominal fat over six months did not clearly help cognition in this trial.